New Sapien 3 TAVR Trial Launched
This article was originally published in The Gray Sheet
Executive Summary
The 600-patient TAVR UNLOAD trial is scheduled to begin enrolling in March to assess Edwards Lifescience's Sapien 3 device in patients with moderate aortic stenosis, a much-expanded market from the device's current labeling.